Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Novartis Lags Q3 Earnings, Announces $12B Avidity Biosciences Acquisition
11:16am, Tuesday, 28'th Oct 2025
Novartis' Q3 profit rose on 8% higher sales led by Kisqali, Kesimpta and Pluvicto, as new acquisitions expand its neuroscience and cardiovascular reach.
Compared to Estimates, Novartis (NVS) Q3 Earnings: A Look at Key Metrics
10:30am, Tuesday, 28'th Oct 2025
While the top- and bottom-line numbers for Novartis (NVS) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compa
Novartis completes acquisition of Tourmaline Bio
09:52am, Tuesday, 28'th Oct 2025
Basel, October 28, 2025 - Novartis today announced that it has successfully completed its acquisition of Tourmaline Bio, Inc. (“Tourmaline”). With the completion of the acquisition, shares of comm
Novartis CEO: We're never done with M&A
08:16am, Tuesday, 28'th Oct 2025
Vas Narasimhan, CEO of pharmaceuticals company, Novartis, discusses the company's latest $12 billion acquisition of Avidity Biosciences, and ongoing negotiations with the U.S. administration over pote
Novartis shares fall as profit lags estimates; downside from Entresto patent loss to continue
06:02am, Tuesday, 28'th Oct 2025
Shares in Swiss drugmaker Novartis were seen down 3.3% in pre-market trade on Tuesday after the company reported third-quarter profitability below market expectations, even as higher sales from key me
Novartis posts Q3 income beat, reaffirms FY2025 guidance
05:47am, Tuesday, 28'th Oct 2025
Swiss pharma giant Novartis sees Q3 income up by a quarter, allowing it to achieve its FY guidance and countering the fall in generic drug sales Stateside. BNP maintains its forecasts despite Q3 net i
Novartis looking to add more medicines to direct to patient platform, CEO says
05:31am, Tuesday, 28'th Oct 2025
Swiss drugmaker Novartis is exploring options to add more medicines to its direct to patient platform that is expected to launch in the U.S. next month, CEO Vas Narasimhan told Reuters in an interview
Novartis CEO says pharma giant has the firepower for big M&A deals: 'Can never be done'
04:17am, Tuesday, 28'th Oct 2025
The Swiss drugmaker announced its biggest deal in a decade on Sunday, as its set to buy Avidity Biosciences for about $12 billion. "We have adequate firepower to do deals like this and to bolster th
Novartis Posts Higher Net Profit as Key Drugs Lift Sales
03:06am, Tuesday, 28'th Oct 2025
The drugmaker reported third-quarter profit of $3.93 billion after higher sales for key drugs allowed it to offset a hit from patent expirations.
Novartis announces expiration of Tourmaline Bio tender offer
02:25am, Tuesday, 28'th Oct 2025
Basel, October 28 2025 - Novartis today announced that its previously announced tender offer (the “offer”) by Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiar
Novartis Q3 operating income up 6% on new drug sales
02:11am, Tuesday, 28'th Oct 2025
Swiss drugmaker Novartis , on a deal-making spree this year, reported a gain in operating income of 6% as growth of its new drugs made up for stagnant revenue from established heart drug Entresto.
Novartis delivers solid sales and core operating income growth with strong pipeline progress in Q3; reaffirms FY 2025 guidance
02:00am, Tuesday, 28'th Oct 2025
Q3 net sales grew +7% (cc1, +8% USD) and core operating income1 grew +7% (cc, +6% USD). Sales growth was driven by continued strong execution on priority brands including Kisqali (+68% cc), Kesimpta (
Avidity Biosciences Soars After $72 Per Share Novartis Takeover
02:52pm, Monday, 27'th Oct 2025
Avidity Biosciences, Inc. (NASDAQ:RNA) stock surged after announcing a $12 billion all-cash acquisition by Novartis AG (NYSE:NVS), marking one of the largest biotech buyouts of the year.
Novartis AG (NVS) M&A Call Transcript
02:27pm, Monday, 27'th Oct 2025
Novartis AG (NYSE:NVS ) M&A Call October 27, 2025 8:00 AM EDT Company Participants Sloan Simpson - Global Head of Investor Relations Vasant Narasimhan - Chief Executive Officer Harry Kirsch - Chief Fi
Why Avidity Biosciences And Dyne Therapeutics Stocks Soared 40% Monday
12:31pm, Monday, 27'th Oct 2025
Shares of Avidity Biosciences (RNA) soared more than 40% Monday after Novartis (NVS) agreed to buy the U.S. biopharmaceutical firm for about $12 billion in cash to expand its RNA-based disease-fightin
